202 related articles for article (PubMed ID: 23848295)
1. Unexpected MH deaths without exposure to inhalation anesthetics in pediatric patients.
Brandom BW; Muldoon SM
Paediatr Anaesth; 2013 Sep; 23(9):851-4. PubMed ID: 23848295
[TBL] [Abstract][Full Text] [Related]
2. Volatile anesthetics and succinylcholine in cardiac ryanodine receptor defects.
Swan H; Laitinen PJ; Toivonen L
Anesth Analg; 2004 Aug; 99(2):435-7, table of contents. PubMed ID: 15271719
[TBL] [Abstract][Full Text] [Related]
3. Novel double and single ryanodine receptor 1 variants in two Austrian malignant hyperthermia families.
Kaufmann A; Kraft B; Michalek-Sauberer A; Weindlmayr M; Kress HG; Steinboeck F; Weigl LG
Anesth Analg; 2012 May; 114(5):1017-25. PubMed ID: 22415532
[TBL] [Abstract][Full Text] [Related]
4. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States.
Larach MG; Brandom BW; Allen GC; Gronert GA; Lehman EB
Anesth Analg; 2014 Dec; 119(6):1359-66. PubMed ID: 25268394
[TBL] [Abstract][Full Text] [Related]
5. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes.
Gonsalves SG; Dirksen RT; Sangkuhl K; Pulk R; Alvarellos M; Vo T; Hikino K; Roden D; Klein TE; Poler SM; Patel S; Caudle KE; Gordon R; Brandom B; Biesecker LG
Clin Pharmacol Ther; 2019 Jun; 105(6):1338-1344. PubMed ID: 30499100
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic testing to diagnose malignant hyperthermia susceptibility.
Girard T; Litman RS
J Clin Anesth; 2008 May; 20(3):161-3. PubMed ID: 18502356
[No Abstract] [Full Text] [Related]
7. Ring fibers visualized by electron microscopy in a Japanese patient with malignant hyperthermia.
Kitagawa Y; Sato J; Kuriyama M; Sano K; Hashimoto K
Odontology; 2011 Jan; 99(1):101-104. PubMed ID: 21271335
[TBL] [Abstract][Full Text] [Related]
8. [Atypical malignant hyperthermia. A higher incidence than expected].
Herrero E; Casinello F; de Stefano J; Fernández-Guisasola J; Pérez-Gallardo A
Rev Esp Anestesiol Reanim; 1996 Jan; 43(1):42-3. PubMed ID: 8851836
[No Abstract] [Full Text] [Related]
9. Duchenne muscular dystrophy: Which is the best anesthetic agent?
Driessen J; Snoeck M
Paediatr Anaesth; 2008 Oct; 18(10):1007-8. PubMed ID: 18811853
[No Abstract] [Full Text] [Related]
10. Malignant hyperthermia susceptibility: utilization of genetic results in an electronic medical record to increase safety.
Baye JF; Petry NJ; Jacobson SL; Moore MM; Tucker B; Shaaban S; Massmann AK; Clark NM; Schultz AJ
Pharmacogenomics; 2020 Nov; 21(17):1207-1215. PubMed ID: 33118445
[No Abstract] [Full Text] [Related]
11. Suxamethonium-induced rhabdomyolysis in a healthy middle-aged man.
Le Puura AI; Koivisto P; Annila P
Acta Anaesthesiol Belg; 2000; 51(1):51-3. PubMed ID: 10806523
[TBL] [Abstract][Full Text] [Related]
12. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.
Brandom BW; Bina S; Wong CA; Wallace T; Visoiu M; Isackson PJ; Vladutiu GD; Sambuughin N; Muldoon SM
Anesth Analg; 2013 May; 116(5):1078-1086. PubMed ID: 23558838
[TBL] [Abstract][Full Text] [Related]
13. The risk of malignant hyperthermia in children undergoing muscle biopsy for suspected neuromuscular disorder.
Flick RP; Gleich SJ; Herr MM; Wedel DJ
Paediatr Anaesth; 2007 Jan; 17(1):22-7. PubMed ID: 17184427
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation in RYR1 and malignant hyperthermia phenotypes.
Carpenter D; Robinson RL; Quinnell RJ; Ringrose C; Hogg M; Casson F; Booms P; Iles DE; Halsall PJ; Steele DS; Shaw MA; Hopkins PM
Br J Anaesth; 2009 Oct; 103(4):538-48. PubMed ID: 19648156
[TBL] [Abstract][Full Text] [Related]
15. [Anesthesia in hereditary peripheral muscular disease].
Islander G; Jungner M
Lakartidningen; 2005 Feb 21-27; 102(8):566-71. PubMed ID: 15786909
[No Abstract] [Full Text] [Related]
16. A multi-dimensional analysis of genotype-phenotype discordance in malignant hyperthermia susceptibility.
Ibarra Moreno CA; Kraeva N; Zvaritch E; Figueroa L; Rios E; Biesecker L; Van Petegem F; Hopkins PM; Riazi S
Br J Anaesth; 2020 Dec; 125(6):995-1001. PubMed ID: 32861507
[TBL] [Abstract][Full Text] [Related]
17. Malignant hyperthermia.
Rosenberg H; Davis M; James D; Pollock N; Stowell K
Orphanet J Rare Dis; 2007 Apr; 2():21. PubMed ID: 17456235
[TBL] [Abstract][Full Text] [Related]
18. [Mild variant of malignant hyperthermia following succinylcholine and halogenated agent exposure].
Fernández-García V; Bermejo MA; Vázquez C; Pereda MJ; Altarriba JM; Alvarez E
Rev Esp Anestesiol Reanim; 1995 Nov; 42(9):401-2. PubMed ID: 8584782
[No Abstract] [Full Text] [Related]
19. [Malignant hyperthermia].
Glahn KP
Ugeskr Laeger; 2003 Apr; 165(17):1763-8. PubMed ID: 12768904
[TBL] [Abstract][Full Text] [Related]
20. Malignant hyperthermia and muscular dystrophies.
Gurnaney H; Brown A; Litman RS
Anesth Analg; 2009 Oct; 109(4):1043-8. PubMed ID: 19762730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
